FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a means for correction of states of cells, different organs and tissues, as well as the human organs and tissues associated with a decrease in the expression of the LIF gene and/or a decrease in the amount of the protein of the factor inhibiting leukemia, based on gene therapeutic substances with the LIF gene, where the organs and tissues cells are selected from fibroblasts, endometrial cells of the uterus, epithelial cells; organs and tissues are selected from the skin, mucous membrane of the mouth or muscle tissue, which is, at least, one gene therapeutic substance selected from the group of gene therapeutic substances, each representing a genetic construct based on a vector plasmid comprising the cDNA of the LIF gene, with the coding sequence of the protein of the factor inhibiting leukemia, with deletions of 5' and 3'-nontranslated regions, in combination with a transport molecule or without it, when these gene therapeutic substances are introduced into human organs and tissues. Group of inventions also relates to a method for the preparation of said agent for treating the human body conditions associated with a decrease in LIF gene expression and/or a decrease in the amount of the protein of a factor inhibiting leukemia; a method of using said agent for treating the human body conditions, associated with a decrease in the expression of the LIF gene and/or a decrease in the amount of the protein of the factor inhibiting leukemia.
EFFECT: group of inventions provides a high and stable level of the target protein in the cells.
5 cl, 20 dwg, 18 ex
